Literature DB >> 3838756

Assay methodology for quantification of the ester and ether glucuronide conjugates of diflunisal in human urine.

D G Musson, J H Lin, K A Lyon, D J Tocco, K C Yeh.   

Abstract

Diflunisal is a salicylate derivative with analgesic and anti-inflammatory properties. It is excreted in the urine as an ether glucuronide, a 1-O-acyl glucuronide and as unchanged drug. The 1-O-acyl glucuronide rearranges to isomeric esters of glucuronic acid under neutral to alkaline pH conditions. The development of a urine assay for the conjugates enables the elucidation of diflunisal non-linear pharmacokinetics. The assay quantitates the ether and ester glucuronides and free diflunisal in urine at 0.5-1.0 micrograms/ml. Analysis of the glucuronides does not require authentic standards.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838756     DOI: 10.1016/0378-4347(85)80049-9

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

1.  The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man.

Authors:  R K Verbeeck; G R Loewen; J I MacDonald; R J Herman
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

2.  Changes in hepatic glycogen cycling during a glucose load in healthy humans.

Authors:  H Stingl; V Chandramouli; W C Schumann; A Brehm; P Nowotny; W Waldhäusl; B R Landau; M Roden
Journal:  Diabetologia       Date:  2005-12-28       Impact factor: 10.122

3.  Quantitation of the pathways of hepatic glycogen formation on ingesting a glucose load.

Authors:  I Magnusson; V Chandramouli; W C Schumann; K Kumaran; J Wahren; B R Landau
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

4.  Pentose pathway in human liver.

Authors:  I Magnusson; V Chandramouli; W C Schumann; K Kumaran; J Wahren; B R Landau
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

5.  Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies.

Authors:  G R Loewen; R J Herman; S G Ross; R K Verbeeck
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.